Virus inducible long noncoding RNA modulator of interferon response (VILMIR)

VILMIR is a novel human long noncoding RNA induced in response to major respiratory viruses and interferon-beta treatment across multiple cell types—including epithelial and immune cells. It acts as an interferon-stimulated gene (ISG), with its expression correlated to both dose and duration of interferon treatment. VILMIR is a direct regulator of the host interferon response, and experimental knockdown of VILMIR leads to broadly reduced transcriptional activation of key ISGs (such as IFIT2 and IFI44L), highlighting its role in modulating the antiviral and innate immune transcriptional program during infection. As such, it represents a promising therapeutic target for modulating host responses to respiratory viral infections, though direct drug targeting and biomarker validation are still in early research stages[1][2][3].

Drugs that modulate the interferon pathway (e.g., JAK inhibitors like ruxolitinib) may indirectly affect VILMIR expression, but no drugs currently target VILMIR directly. VILMIR regulates the magnitude of host transcriptional response to IFN-β; knockdown reduces the expression of interferon-stimulated genes such as IFIT2 and IFI44L.